Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval for Additional Doses to Treat Type 2 Diabetes

 Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval for Additional Doses to Treat Type 2 Diabetes

Eli Lilly’s Trulicity (dulaglutide) Receives the US FDA’s Approval for Additional Doses to Treat Type 2 Diabetes

Shots:

  • The approval is based on P-III AWARD-11 study assessing Trulicity (3.0mg & 4.5mg, qw) vs Trulicity (1.5 mg) in 1,842 patients with T2D
  • The P-III study demonstrated that additional doses led to further benefits in A1C (-17% & -19% vs -1.5%) and bodyweight reduction (-8.8 & -10.4 vs -6.8 pounds) @36wks. in people with inadequately controlled T2D on concomitant metformin therapy respectively
  • The P-III study results are under EMA’s review for approval, expected this year. The additional doses of Trulicity will be available in US’ pharmacies later this month

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: S&P Global

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post